PROTHENA PLC (PRTA)
Health Care · NASDAQ
A clinical-stage biotech developing antibody therapies targeting misfolded proteins in Parkinson's disease, Alzheimer's disease, and rare amyloidosis through proprietary CYTOPE® intracellular delivery technology, in partnership with major pharma.
What PROTHENA PLC does
Prothena is a late-stage clinical biotechnology company focused on discovering and developing therapeutic candidates targeting protein dysregulation and misfolded proteins associated with neurodegenerative and rare peripheral amyloid diseases. The company's pipeline includes partnered programs for Parkinson's disease, ATTR amyloidosis, Alzheimer's disease, and ALS, alongside proprietary CYTOPE® technology for intracellular delivery. The company is advancing clinical programs in partnership with major pharmaceutical companies including Roche, Novo Nordisk, and Bristol Myers Squibb.
Themes: ["Parkinson's disease / synucleinopathies","ATTR amyloidosis","Alzheimer's disease","Amyotrophic lateral sclerosis (ALS)","Protein misfolding / amyloid diseases","CNS / neurodegeneration","Monoclonal antibodies","Cell-internalizing delivery technology"]
Fundamentals
- Price$9.64 as of 2026-07-09 close
- Market cap$516M as of 2026-07-10
- 1-year return+46.5% as of 2026-07-09 close
- Net margin-260.9% as of 2026-07-10
- ROE-49.9% as of 2026-07-10
- Debt / equity0.00 as of 2026-07-10
- Revenue growth (YoY)-58.0% as of 2026-07-10
- Revenue CAGR (3y)-43.6% SEC XBRL
- Beta-0.39 as of 2026-07-10
Key risks (from latest filing)
["Clinical development failure risk — most programs are in Phase 2-3 trials with uncertain regulatory approval; prasinezumab Phase 3 trial results critical to valuation","Dependence on major pharma partnerships — primary revenue and development success rely on Roche, Novo Nordisk, and Bristol Myers Squibb; partnership terminations or setbacks would significantly impact financials","Severe unprofitability and cash burn — company is deeply unprofitable (net margin -260.92%) with declining revenue (-57.99% YoY), creating ongoing funding and runway risks"]
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.